The stock has a 36-month beta value of 1.18. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ONVO is 1.70M, and at present, short sellers hold a 4.32% of that float. On April 11, 2025, the average trading volume of ONVO was 662.21K shares.
ONVO) stock’s latest price update
Organovo Holdings Inc (NASDAQ: ONVO)’s stock price has plunge by 2.83relation to previous closing price of 2.12. Nevertheless, the company has seen a 0.46% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-02 that SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capital Market should the closing price of its common stock remain at similar levels.
ONVO’s Market Performance
Organovo Holdings Inc (ONVO) has seen a 0.46% rise in stock performance for the week, with a -57.85% decline in the past month and a -57.85% plunge in the past quarter. The volatility ratio for the week is 13.26%, and the volatility levels for the past 30 days are at 14.21% for ONVO. The simple moving average for the past 20 days is -24.30% for ONVO’s stock, with a -60.94% simple moving average for the past 200 days.
Analysts’ Opinion of ONVO
Many brokerage firms have already submitted their reports for ONVO stocks, with H.C. Wainwright repeating the rating for ONVO by listing it as a “Buy.” The predicted price for ONVO in the upcoming period, according to H.C. Wainwright is $2.50 based on the research report published on December 13, 2018 of the previous year 2018.
ONVO Trading at -51.76% from the 50-Day Moving Average
After a stumble in the market that brought ONVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.07% of loss for the given period.
Volatility was left at 14.21%, however, over the last 30 days, the volatility rate increased by 13.26%, as shares sank -54.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.68% lower at present.
During the last 5 trading sessions, ONVO rose by +0.46%, which changed the moving average for the period of 200-days by -77.00% in comparison to the 20-day moving average, which settled at $2.88. In addition, Organovo Holdings Inc saw -60.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONVO
Current profitability levels for the company are sitting at:
- -102.93 for the present operating margin
- -0.19 for the gross margin
The net margin for Organovo Holdings Inc stands at -101.52. The total capital return value is set at -13.85. Equity return is now at value -378.40, with -194.66 for asset returns.
Based on Organovo Holdings Inc (ONVO), the company’s capital structure generated 0.74 points at debt to capital in total, while cash flow to debt ratio is standing at -9.53. The debt to equity ratio resting at 2.91. The interest coverage ratio of the stock is -2511.6.
Currently, EBITDA for the company is -14.81 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 29.58. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
To sum up, Organovo Holdings Inc (ONVO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
